| Placebo (mg/day) (N = 76) | Tolvaptan | P value | |||||||
---|---|---|---|---|---|---|---|---|---|---|
7.5 mg/day (N = 153) | 15 mg/day (N = 304) | |||||||||
Mean ± SD | Changes from baseline | Mean ± SD | Changes from baseline | Mean ± SD | Changes from baseline | 7.5 mg/day tolvaptan versus placebo | 15 mg/day mg tolvaptan versus placebo | 7.5 mg/day versus 15.0 mg/day tolvaptan | ||
Serum creatinine (mg/dL) | Baseline | 0.8 ± 0.2 | – | 0.8 ± 0.3 | – | 0.9 ± 0.3 | – | – | – | – |
Day 4 | 0.8 ± 0.2 | 0.0 ± 0.1 | 0.9 ± 0.3 | 0.1 ± 0.2 | 0.9 ± 0.3 | 0.1 ± 0.2 | 0.030 | 0.001 | 0.173 | |
Day 7 | 0.8 ± 0.2 | 0.0 ± 0.2 | 0.9 ± 0.3 | 0.1 ± 0.2 | 0.9 ± 0.3 | 0.1 ± 0.2 | 0.119 | 0.019 | 0.517 | |
BUN (mmol/L) | Baseline | 6.2 ± 3.0 | – | 6.3 ± 3.4 | – | 6.8 ± 3.6 | – | – | – | – |
Day 4 | 5.8 ± 2.7 | − 0.1 ± 1.0 | 6.2 ± 3.4 | 0.1 ± 1.6 | 6.5 ± 3.6 | − 0.1 ± 1.7 | 0.428 | 0.871 | 0.434 | |
Day 7 | 6.7 ± 3.4 | 0.5 ± 2.5 | 6.8 ± 4.0 | 0.5 ± 2.5 | 6.7 ± 3.9 | 0.0 ± 2.0 | 0.987 | 0.086 | 0.027 | |
TB (µmol/L) | Baseline | 43.8 ± 42.1 | – | 49.2 ± 57.2 | – | 43.6 ± 47.7 | – | – | – | – |
Day 4 | 40.7 ± 37.4 | 0.6 ± 11.1 | 45.6 ± 45.0 | 1.1 ± 13.6 | 46.4 ± 57.5 | 2.8 ± 21.0 | 0.809 | 0.252 | 0.317 | |
Day 7 | 44.8 ± 52.8 | 2.6 ± 21.7 | 48.2 ± 50.4 | 3.4 ± 23.7 | 44.6 ± 58.0 | 0.8 ± 20.2 | 0.822 | 0.526 | 0.260 | |
AST (IU/L) | Baseline | 67.4 ± 54.9 | – | 68.8 ± 56.9 | – | 66.0 ± 54.2 | – | – | – | – |
Day 4 | 68.6 ± 61.0 | 3.0 ± 15.2 | 65.7 ± 55.3 | 0.2 ± 20.8 | 65.0 ± 57.9 | − 0.6 ± 22.7 | 0.280 | 0.133 | 0.741 | |
Day 7 | 68.1 ± 66.2 | 2.0 ± 18.6 | 71.0 ± 64.5 | 4.0 ± 32.7 | 69.5 ± 66.1 | 2.2 ± 36.7 | 0.573 | 0.951 | 0.614 | |
ALT/GPT (IU/L) | Baseline | 42.2 ± 27.1 | – | 43.1 ± 37.7 | – | 44.2 ± 39.3 | – | – | – | – |
Day 4 | 40.5 ± 26.8 | − 1.1 ± 8.8 | 42.0 ± 36.9 | 0.6 ± 12.8 | 44.0 ± 35.0 | − 0.5 ± 18.5 | 0.274 | 0.712 | 0.467 | |
Day 7 | 39.3 ± 26.9 | − 1.8 ± 11.6 | 44.3 ± 40.0 | 1.9 ± 19.8 | 45.5 ± 39.5 | 0.4 ± 30.3 | 0.087 | 0.335 | 0.529 |